How life sciences companies build and align their commercial, medical, and market access strategies is one of the four areas where Vintura works with life sciences organisations. Getting strategy right across all three functions simultaneously, and keeping it coherent as markets evolve, is what determines whether a therapy reaches its potential.
The Challenges
A good product is no longer a guarantee for success
At the same time that the evidentiary bar is rising, Commercial, Market Access, and Medical Affairs are each being asked to do fundamentally more than they were built to do. The organisations that succeed are the ones that build strategies genuinely responsive to what the environment now requires, and that keep those strategies aligned across functions as conditions change.
How does your commercial organisation predict and adapt quickly to changes in the external environment? Do you have an aligned and synergised commercial strategy that different functions can collaborate on as one team, in one voice?
Brand plans that do not reflect the full picture
Brand plans are frequently built in isolation or without genuine cross-functional alignment. They may hold together commercially on paper, but are often disconnected from the patient pathway, misaligned with what payers are actually asking, and inconsistent with what Medical Affairs communicates externally. The result is a strategy that looks complete in the planning room but creates friction at every stakeholder touchpoint in the market.
Portfolio decisions that do not keep pace with the market
A portfolio decision made two years before launch can be the wrong one by the time the therapy reaches market. Competitive landscapes shift, payer priorities evolve, and new clinical data changes what HCPs believe about unmet need. Too many organisations treat portfolio prioritisation as a fixed decision rather than a live process, and arrive at launch with a strategy built for a market that no longer exists. Portfolio choices are too often made on clinical merit or internal financial logic alone, without unfiltered input from HCPs on what they will actually prescribe, or from access teams on what the system will actually reimburse.
Digital technologies are reshaping the rules faster than most organisations are moving
Digital capability in life sciences is moving from competitive advantage to baseline expectation. Organisations building digital infrastructure into the core of their commercial and medical strategy will move faster, engage more intelligently, and generate better evidence than those treating it as a future priority. The window to build that capability before it becomes a structural disadvantage is narrowing. New entrants from the technology and digital sector are also entering the industry, requiring established biotech and pharma companies to rethink their commercial assumptions.
Patient empowerment is changing who holds commercial organisations accountable
Patients and patient organisations are increasingly informed, organised, and able to hold both manufacturers and health authorities accountable for the affordability and accessibility of innovative medicines. A commercial strategy that does not incorporate patient perspective from early development will find itself at a disadvantage with every stakeholder that matters: payers, providers, HTA bodies, and the patients themselves.
Value is now the dominant language of every stakeholder conversation
Every stakeholder conversation, whether with payers, providers, patient organisations, or HTA bodies, now centres on the same question: what is the value of this therapy for the system as a whole? Commercial strategies that cannot answer that question with credible, access-ready evidence will hit reimbursement barriers that no amount of marketing effort can fix. The value narrative must be built early and aligned across functions.
Asset and portfolio strategy go hand in hand, and both should be a dynamic response to market evolution. In one specific case, we were brought in to support a global product launch, but it became clear that the real question was not how to launch the asset, but how the company should position its entire portfolio against a rapidly evolving competitive landscape.
Our Approach
Strategy that spans the full breadth of the commercial model
Vintura works across all core functions that together determine whether a life sciences strategy succeeds: R&D, Commercial, Medical Affairs, and Market Access. A strategy developed within a single function will always be partial. The decisions made in each function have direct consequences for the others, and the organisations that win are the ones that build strategies coherent across all three simultaneously.
Product and Portfolio Strategy — from early pipeline prioritisation to late lifecycle management
Strong commercial strategy operates at two levels simultaneously. At the portfolio level, it means making well-informed choices across assets: evaluating pipeline opportunities, prioritising and sequencing indications, and assessing the trade-off between investment and opportunity for each.
At the product level, it means building the value story and strategic foundation that determines whether a therapy reaches its potential in market. Vintura works with Commercial, Medical Affairs, Market Access, and R&D functions across this full span: market and competitive landscaping, pipeline and portfolio prioritisation, brand positioning and differentiation, launch planning and acceleration, go-to-market strategy, pricing and reimbursement assessment, HTA readiness, access scenario planning, lifecycle management, and the evidence generation and scientific platform strategy that underpins it all.
The decisions made in early development regarding clinical endpoints, target populations, and indication sequencing will determine what level of access is achievable. Vintura helps clients make those decisions with the commercial and access consequences already in view.
Strategic Partnering — accessing innovation and growth beyond your own capabilities
Innovation in life sciences increasingly happens at the edges of organisations: in biotech, in academia, and in digital health. The ability to identify, evaluate, and structure the right partnerships is therefore a strategic capability in its own right. Vintura supports clients in partner and technology searches, opportunity assessments, and the structuring of business development and licensing deals that create genuine value on both sides of the table.
Patient-Centric Solutions — embedding patient perspective from the outset
Commercial strategies that cannot answer the value question with credible, access-ready evidence will hit reimbursement barriers that marketing spend cannot fix. The value narrative must be built early and owned across functions. Vintura helps clients make patient centricity operational: mapping the patient journey, integrating patient voice into evidence generation and commercial planning, and ensuring the strategy reflects what access and outcomes actually mean to the people the therapy is designed to serve.
Digital and AI Solutions — from capability gap to commercial advantage
Digital has moved from a future priority to a present requirement in life sciences strategy. Vintura helps clients assess their current digital maturity, identify where digital investment will generate the most commercial and access value, and translate that into a strategy grounded in practical implementation rather than aspiration.
A great commercial strategy functions like a lighthouse, not just for the teams building it, but also for the healthcare ecosystem it is meant to serve.
What Good Looks Like
A solid commercial strategy cuts through complexity, signals a clear therapeutic and commercial point of view, and aligns cross-functional teams around a shared mission: improving patient outcomes. It is built on a robust understanding of the gaps in evidence and patient pathways, makes conscious evidence-based choices about where to focus — which unmet needs, which sub-populations, which gaps along the pathway — and produces clarity of purpose that builds genuine trust with the healthcare community.
For the product
A launch that hits its trajectory is not simply the result of a stronger product. It is the result of a plan built with genuine cross-functional input from the start, where Commercial, Medical Affairs, and Market Access shape the plan together, and where key regional teams were involved early enough to flag what would not survive contact with the market. When those conditions are in place, a launch does not just start well. It sustains.
For the portfolio
A strong product strategy must make sense within the portfolio it sits in. A value story that conflicts with another asset’s positioning, or that pulls patients who would be better served by a different therapy in the same portfolio, creates a strategic problem that compounds over time. What good looks like is a brand position that is differentiated externally and coherent internally, one that expands the addressable patient population rather than redistributing it.
For the patient
Better upstream alignment produces better patient outcomes. A value narrative that resonates with payers, a launch plan grounded in the real patient pathway, and evidence structured around access requirements rather than only clinical development logic are what it takes to close the gap between regulatory approval and patients actually receiving the right treatment.
From scientific innovation to real-world impact
The gap between scientific innovation and real-world patient impact is rarely a science problem. In practice, the patients who need a therapy most are often the ones who cannot access it, for reasons that have nothing to do with its clinical profile: pathway inefficiencies, economic constraints, or gaps in HCP capability and awareness. These are solvable problems. But they are only solvable if the commercial strategy is designed to address them from the start, with patient centricity built into the foundation rather than added at launch.
That means making deliberate choices early: which unmet needs to prioritise, which sub-populations to focus on, which gaps along the pathway to close. It means structuring evidence generation around what access actually requires, not only around what clinical development would naturally produce. And it means ensuring that the value narrative is coherent across Commercial, Medical Affairs, and Market Access before it reaches any external stakeholder. Until those conditions are in place, no amount of HCP engagement or KOL advocacy will consistently close the gap between approval and impact.
Let’s talk
Ready to build a strategy that holds together across functions, markets, and through the full product lifecycle?
Every commercial strategy challenge is different. Some organisations need help aligning functions that have drifted apart. Others are approaching a launch and realise the value story is not yet ready for the payer conversations ahead. Some are rethinking their portfolio in response to a shifting competitive landscape. Wherever you are, the starting point is the same: a conversation with someone who understands the full picture.
Poka Cui and Louise Soh work with life sciences companies across all stages of commercial strategy development, from early pipeline decisions to late lifecycle management. They bring both the strategic frameworks and the cross-functional experience to help you move from where you are to where you need to be. Reach out directly, or share where you are and they will take it from there.
